23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
20:35 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves Astellas’ Xospata in FLT3-positive AML

FDA approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation. The company said Xospata is the first...
21:56 , Nov 28, 2018 |  BC Extra  |  Company News

FDA approves Astellas’ Xospata in FLT3-positive AML

FDA approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) to treat relapsed or refractory acute myelogenous leukemia in patients with an FMS-like tyrosine kinase 3 (FLT3; CD135) mutation. The company plans to launch the drug,...
18:46 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Mirati reports updated confirmed ORR of 16% in Phase II of sitravatinib for NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1...
18:11 , Oct 22, 2018 |  BC Extra  |  Clinical News

Mirati falls on updated response data for sitravatinib in NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data Monday from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus...
17:25 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta...
17:23 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best...
19:34 , Sep 25, 2018 |  BC Extra  |  Clinical News

Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall...
21:45 , Sep 21, 2018 |  BC Extra  |  Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

EMA's CHMP Friday recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam. CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT)...